Investigational Compound Dapagliflozin Sustained Glycemic Control and Weight Reduction in Study of Type 2 Diabetes Patients Inadequately Controlled with Metformin
Links shared publicly online about this topic.
- 192total visits
Investigational Compound Dapagliflozin Sustained Glycemic Control and Weight Reduction in Study of Type 2 Diabetes Patients Inadequately Controlled with Metformin
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from an exploratory 78-week study extension of a Phase 3
View full resource at businesswire.com
Tags: Diabetes, Diabetes Type 2 Medication, Diabetes Medication, Type 2 Diabetes, Weight Loss, Glucophage, AstraZeneca, Bristol-Myers Squibb
Most Recently Shared on June 25, 2011 at 8:43 pm By:
Investigational Compound Dapagliflozin Sustained Glycemic Control and Weight Reduction in Study of T2D http://bit.ly/kOZrXt
Advertisement
